Literature DB >> 18570271

The assessment of non-inferiority in a gold standard design with censored, exponentially distributed endpoints.

Matthias Mielke1, A Munk, A Schacht.   

Abstract

The objective of this paper is to develop statistical methodology for non-inferiority hypotheses to censored, exponentially distributed time to event endpoints. Motivated by a recent clinical trial in depression, we consider a gold standard design where a test group is compared with an active reference and with a placebo group. The test problem is formulated in terms of a retention of effect hypothesis. Thus, the proposed Wald-type test procedure assures that the effect of the test group is better than a pre-specified proportion Delta of the treatment effect of the reference group compared with the placebo group. A sample size allocation rule to achieve optimal power is presented, which only depends on the pre-specified Delta and the probabilities for the occurrence of censoring. In addition, a pretest is presented for either the reference or the test group to ensure assay sensitivity in the complete test procedure. The actual type I error and the sample size formula of the proposed tests are explored asymptotically by means of a simulation study showing good small sample characteristics. To illustrate the procedure a randomized, double blind clinical trial in depression is evaluated. An R-package for implementation of the proposed tests and for sample size determination accompanies this paper on the author's web page. Copyright 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18570271     DOI: 10.1002/sim.3348

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  4 in total

1.  Group-sequential three-arm noninferiority clinical trial designs.

Authors:  Toshimitsu Ochiai; Toshimitsu Hamasaki; Scott R Evans; Koko Asakura; Yuko Ohno
Journal:  J Biopharm Stat       Date:  2016-02-18       Impact factor: 1.051

Review 2.  The averted infections ratio: a novel measure of effectiveness of experimental HIV pre-exposure prophylaxis agents.

Authors:  David T Dunn; David V Glidden; Oliver T Stirrup; Sheena McCormack
Journal:  Lancet HIV       Date:  2018-06       Impact factor: 12.767

3.  New approaches for testing non-inferiority for three-arm trials with Poisson distributed outcomes.

Authors:  Samiran Ghosh; Erina Paul; Shrabanti Chowdhury; Ram C Tiwari
Journal:  Biostatistics       Date:  2022-01-13       Impact factor: 5.899

4.  Effects of three home-based exercise programmes regarding falls, quality of life and exercise-adherence in older adults at risk of falling: protocol for a randomized controlled trial.

Authors:  Anne-Gabrielle Mittaz Hager; Nicolas Mathieu; Constanze Lenoble-Hoskovec; Jaap Swanenburg; Rob de Bie; Roger Hilfiker
Journal:  BMC Geriatr       Date:  2019-01-14       Impact factor: 3.921

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.